AstraZeneca Hits 4-week High
Sanofi will invest approximately 1 billion euros to build a new insulin production base in peking.
Sanofi will invest approximately 1 billion euros (about 1.1 billion US dollars) to build a new insulin production facility in Peking, marking its largest single investment in china to date and part of its broader global strategy to expand production capacity in asia. The French pharmaceutical company stated on WeChat that this will be Sanofi's fourth production facility in china and its second in Peking, focusing on meeting the medication needs of local diabetes patients. Sanofi is one of the largest insulin producers globally, and the potential in the diabetes treatment market in china is immense. Sanofi noted that as of 2021, around 0.14 billion adults in mainland china suffer from diabetes.
Sanofi Unveils $1 Billion China Investment to Boost Production
AstraZeneca PLC ADR Falls Monday, Underperforms Market
AstraZeneca Announces Share Capital and Voting Rights
Why AstraZeneca PLC (AZN) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
loading...
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
